Background: RAD51D is involved in DNA double-strand break repair by homologous recombination and plays an important role in the maintenance of genomic stability. The associations between RAD51D germline mutations and breast cancer risk and survival are not fully elucidated.
Introduction
RAD51D (RAD51 paralog D) is an important DNA repair gene and is involved in the homologous recombination pathway [1, 2] . Rad51d-deficient mouse cells exhibit extensive genomic instabilities, such as aneuploidy, chromosome fragments, deletions, rearrangements and a spontaneous increase in random mutagenesis [3, 4] . These genomic deficiencies suggest that RAD51D may be associated with tumorigenesis.
RAD51D deleterious germline mutations are significantly associated with an increased ovarian cancer risk; the relative risk of ovarian cancer was estimated to be 6.30 for RAD51D mutation carriers [5] , indicating that RAD51D is an ovarian cancer susceptibility gene. Subsequent studies have further confirmed that RAD51D are ovarian cancer predisposition gene [6] [7] [8] [9] . Although RAD51D deleterious mutations were found in breast cancer patients in the breast and/or ovarian cancer families, no deleterious RAD51D germline mutation was found in breast cancer patients without a family history of breast and/or ovarian cancer in several studies with relatively small sample sizes (ranged from 171 to 747) [5, [8] [9] [10] [11] . Thus, the association between RAD51D germline mutations and breast cancer risk remains unclear. On the other hand, a few RAD51D germline mutations were found in breast cancer patients by next-generation sequencing in some multicenter studies [12] [13] [14] [15] [16] [17] , suggesting that RAD51D germline mutations might be associated with breast cancer risk. However, few case-control studies with large sample sizes are available for investigating the association between breast cancer risk and RAD51D germline mutations to date. More importantly, no studies have investigated the association between RAD51D germline mutations and survival in breast cancer patients.
In this study, we determined RAD51D germline mutations among 7657 BRCA1/2-negative breast cancer patients who were unselected for age at diagnosis or family history of breast cancer and screened for the RAD51D recurrent mutation p.K91fs in 7947 healthy controls; we further explored the associations between the RAD51D germline mutation carriers and clinicopathological characteristics. Finally, we compared the survival of the RAD51D mutation carriers and noncarriers in terms of recurrence-free survival (RFS) and distant recurrence-free survival (DRFS) in the entire cohort of 7657 patients.
Patients and methods

Patients
A total of 8085 consecutive primary breast cancer patients who were treated at the Breast Center of Peking University Cancer Hospital from 2003 to 2015 received a multigene panel testing, as previously described [18] . Among these, 428 patients who carried deleterious BRCA1/2 germline mutations were excluded. The remaining 7657 BRCA1/2-negative primary breast cancer patients were enrolled in this study (supplementary Table S1 , available at Annals of Oncology online). The patients' ages at diagnosis ranged from 19 to 98 years, with a median age of 50 years.
The study was approved by the Ethics Committee of Peking University Cancer Hospital (No.2011KT12), and written informed consent was obtained from all participants.
Panel-based sequencing assay
Germline DNA samples from 7657 patients with breast cancer underwent custom capture (SeqCap EZ) of protein-coding exons and adjacent splice sites (15 bp) from 62 cancer susceptibility genes, including RAD51D. The sequencing library preparation and analysis of sequencing data were described in detail in our previous study [18] . All RAD51D variants were named according to Human Genome Variation Society (HGVS) nomenclature using the NCBI transcript ID NM_002878.3 as a reference sequence. Only the mutations that were frameshift or nonsense were considered to be deleterious. All deleterious mutations were validated by independent Sanger sequencing.
Screening RAD51D p.K91fs mutation in control
To estimate the frequency of the recurrent mutation p.K91fs of RAD51D in Chinese women, a total of 7947 unrelated healthy women served as controls.
In 7947 healthy controls, genomic DNA was extracted from peripheral blood samples by standard methods. Then, the DNA was amplified by the primers spanning exons 4-5 (5 0 -CTCCTGGCCAGTGATGTTCA-3 0 and 5 0 -GCATCAACAGGGGTGGCTTA-3 0 ). The products were purified and then sequenced on an ABI 3730 automated sequencer (Applied Biosystems) to screen the RAD51D p.K91fs mutation. All mutations were validated by Sanger sequencing in duplicate.
RAD51D p.K91fs haplotype analysis
Haplotype analyses were carried out using short tandem repeat (STR) markers D17S1850, D17S1293, D17S1842, D17S933, D17S1846 and D17S1833 surrounding the RAD51D region. The six STR markers span a region of approximately 2 Mb (2 million base pairs of DNA) on chromosome 17q flanking RAD51D (at chr17: 33, 810, 711-35, 797, 201; hg19). Each marker was amplified with fluorescently labeled primers. The PCR products were analyzed using an ABI3730 analyzer with GeneMapper software (Applied Biosystems). Primer sequences for the 6 STR markers are listed in PubMed (https://www.ncbi.nlm.nih.gov).
Statistical analysis
Association between the RAD51D p.K91fs mutation and the risk of unselected breast cancer was tested by logistic-regression analysis; odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Categorical variables were compared between RAD51D mutation carriers and noncarriers using the Chi square test or the Fisher exact test, where appropriate. Continuous variables were tested with a t test. RFS was calculated from the date of diagnosis to the date of the first recurrence (local or distant) but not including contralateral breast cancer or death from breast cancer (for patients without a recorded relapse) or to last follow-up. DRFS was calculated from the date of diagnosis to the date of the first distant recurrence or death from breast cancer (for patients without a recorded relapse) or to last follow-up. Patients who died from causes other than breast cancer were censored at the time of death. Survival analysis was estimated using the Kaplan-Meier product-limit method and differences were tested for statistical significance using the log-rank test. A Cox proportional hazards model was used to determine whether a factor was associated with survival. Two-sided P values <0.05 were considered to be statistically significant. All analyses were carried out using SPSS 21.0 software (Chicago, IL).
Results
Prevalence of RAD51D germline mutations in breast cancer RAD51D germline mutations were determined in this large cohort of 7657 unselected BRCA1/2-negative breast cancer patients. A total of 30 RAD51D deleterious germline mutations were identified in 29 of the 7657 unselected BRCA1/2-negative breast cancer patients (Table 1) . One patient carried two RAD51D deleterious mutations, p.L8fs and p.R186X. The prevalence of RAD51D mutations in this cohort was 0.38% (29 of 7657).
Notably, 18 (0.24%) of the 7657 breast cancer patients carried the RAD51D p.K91fs mutation, which represented 60% of all RAD51D mutations. In addition, another three recurrent mutations were also identified in this cohort: p.R186X (two unrelated cases), p.R253X (three unrelated cases) and p.R300X (four unrelated cases). Recurrent mutations accounted for 90.0% of all RAD51D mutations (Table 1 ). All the deleterious mutations identified in RAD51D were clustered in the C-terminal region (residues 78 to 328). Exons 4 and 9 were the most frequently mutated, accounting for 86.7% of all RAD51D mutations (Figure 1 ).
RAD51D p.K91fs mutation and breast cancer risk
We carried out a case-control study to investigate the association between breast cancer risk and RAD51D p.K91fs mutation ( Table 2 ). The p.K91fs mutation was found in 8 of 7947 healthy controls with a frequency of 0.10%. The p.K91fs mutation was significantly associated with increased breast cancer risk in unselected BRCA1/2-negative breast cancer (OR ¼ 2.34, 95% CI 1.02-5.38; P ¼ 0.040) ( Table 2 ). The RAD51D p.K91fs mutation conferred a moderately increased risk of breast cancer. Furthermore, we found that RAD51D p.K91fs mutation was more pronounced associated with an increased breast cancer risk in triple-negative breast cancer patients when compared with estrogen receptor (ER) positive and/or progesterone receptor (PR) positive and HER2-negative patients (supplementary Table S2 , available at Annals of Oncology online) and was more pronounced associated with an increased breast cancer risk in breast cancer patients who are diagnosed at and before the age of 40 years when compared with those who are diagnosed over the age of 40 years (supplementary Table S3 , available at Annals of Oncology online).
To determine whether recurrent mutation p.K91fs was due to a founder effect, 6 STR markers flanking the RAD51D gene were selected, and haplotypes were determined in 18 unrelated RAD51D p.K91fs mutation carriers. The common haplotype was not observed in 18 RAD51D p.K91fs mutation carriers. We concluded that the p.K91fs mutations occurred as independent mutational events rather than from a common ancestry.
RAD51D mutation and tumor characteristics
The detailed clinical information of 29 RAD51D mutant patients is presented in supplementary Table S4 , available at Annals of Oncology online. The mean age at diagnosis of breast cancer among RAD51D mutation carriers was significantly younger when compared with that among noncarriers (45.4 years versus 51.3 years, P ¼ 0.006) ( Table 3 ). RAD51D mutation carriers were significantly more likely to be triple-negative cancers than noncarriers (34.5% versus 13.3%, P ¼ 0.003) (Table 3) , and RAD51D mutation carriers were more likely to have high-grade tumors (33.3% versus 15.4%, P ¼ 0.023), positive axillary lymph nodes (43.4% versus 27.3%, P ¼ 0.024), and ER-negative tumors (51.7% versus 28.1%, P ¼ 0.005) than noncarriers (Table 3) . No significant differences in family history of breast cancer, PR status, HER2 status, or tumor size were observed between RAD51D mutation carriers and noncarriers (Table 3) .
Survival
In this cohort of 7657 BRCA1/2-negative breast cancer patients, 109 patients who were stage IV when diagnosed with breast cancer were excluded for survival analysis. The follow-up data for 53 Figure 1 . Deleterious mutations identified in RAD51D gene among 7657 BRCA1/2-negative unselected breast cancer patients. patients were not available. Therefore, the remaining 7495 (97.9%) breast cancer patients were included in survival analysis, which included 28 RAD51D mutation carriers and 7467 noncarriers. The median follow-up time was 50 months (range, 1-152 months).
The 5-year RFS rates for the RAD51D mutation carriers and noncarriers were 67.7% (95% CI 47.5%-87.9%) and 88.7% (95% CI 87.9%-89.5%), respectively; the 5-year DRFS rates for the RAD51D mutation carriers and noncarriers were 78.0% (95% CI 60.4%-95.6%) and 90.4% (95% CI 89.6%-91.2%), respectively. RAD51D mutation carriers exhibited a significantly worse RFS [unadjusted hazard ratio (HR) ¼ 3.00, 95% CI 1.56-5.80; P ¼ 0.001) and DRFS (unadjusted HR ¼ 2.54, 95% CI 1.14-5.67; P ¼ 0.023) than noncarriers (supplementary Table S5 , available at Annals of Oncology online and Figure 2) .
Furthermore, in multivariate analysis, RAD51D mutation carriers showed a significantly worse RFS (adjusted HR ¼ 2.35, 95% CI 1.10-4.99; P ¼ 0.027) and a trend for worse DRFS (adjusted HR ¼ 2.12, 95% CI 0.87-5.16; P ¼ 0.10) after adjustment for age, tumor size, lymph node, tumor grade, ER, PR, HER2 status, and treatment (supplementary Table S6 , available at Annals of Oncology online).
Discussion
We found that 0.38% of patients carried RAD51D germline mutations in the 7657 unselected BRCA1/2-negative breast cancer patients. In previous studies, only a few RAD51D germline mutations have been reported in breast cancer patients who are highly selected for age at diagnosis and family history of cancer by next-generation sequencing assays. In these studies, the RAD51D mutation frequency ranged from 0.07% to 0.19% [15] [16] [17] . Although our patients were unselected, the prevalence of RAD51D germline mutations was higher than that in other ethnic groups. The possible reason was that the p.K91fs mutation was more common in our population.
The majority of the RAD51D deleterious mutations in our large cohort were clustered in the C-terminal region, which is consistent with the distribution of RAD51D mutations in ovarian cancer [6] . Mutations in the C-terminal domain of RAD51D gene impair the function of double-strand DNA break repair through the homologous recombination pathway [19] .
In this study, we found that four recurrent mutations accounted for 90% of all RAD51D mutations. Of these, the RAD51D p.K91fs recurrent mutation is remarkable and accounted for 60% of all RAD51D mutations. Although the RAD51D p.K91fs mutation has also been found in British breastovarian cancer families [5, 9] , the frequency of the p.K91fs mutation in these studies was much lower than that in our cohort. Thus, we carried out a haplotype analysis to determine whether it was a Chinese founder mutation. However, the mutation carriers had different genotyping by six STR markers, suggesting that the RAD51D p.K91fs is not a founder mutation in Chinese women.
Germline mutations in RAD51D genes in breast cancer are rare; many previous studies did not have enough breast cancer cases with RAD51D mutations to assess the breast cancer risk. A recent study found 5 cases carrying RAD51D germline mutations in 5589 BRCA1/2-negative breast cancer cases, and no mutations were found in 2189 matched controls [17] . This study suggested that RAD51D germline mutations are associated with breast cancer risk. In our study, the RAD51D recurrent mutation p.K91fs was found in 0.24% of 7657 BRCA1/2-negative breast cancer patients, whereas the recurrent mutation was found in 0.10% of 7947 geographically matched healthy controls, indicating that RAD51D recurrent mutation p.K91fs confers a moderately increased risk of breast cancer. This finding is consistent with a recent study that RAD51D is associated with a moderate increased breast cancer risk (OR ¼ 3.07, 95% CI 1.21-7.88); this study is involved in 25 950 breast cancer patients tested with a multigene panel and uses the database of Exome Aggregation Consortium (ExAC) as a control [15] .
We found that RAD51D mutation carriers were more likely to be early-onset breast cancer; the mean age at diagnosis of RAD51D mutation carriers (45.4 years) is similar to that of patients with BRCA1 (44.8 years) mutation [18] . Although RAD51D is an ovarian cancer susceptibility gene, only 1 of the 29 RAD51D mutation carriers had a family history of ovarian cancer in our study. RAD51D mutation carriers were more likely to have higher grade tumor, ER negative tumor, axillary lymph node positive tumor and the presence of triple-negative breast cancer, indicating that RAD51D mutation carriers have an aggressive phenotype. RAD51D mutation carriers showed a significantly worse RFS and DRFS when compared with noncarriers. In multivariate analysis, RAD51D mutation carriers had a significantly worse RFS and a tendency toward worse DRFS than noncarriers. Previous studies have shown that RAD51D-deficient cells respond to the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib [5] . Therefore, breast cancer patients carrying RAD51D mutations may be potential candidates for treatment with PARP inhibitors in clinical trials, like BRCA1/2 mutation carriers [20] .
There are two main limitations to our study. First, we only found that the p.K91fs recurrent mutation is associated with increased breast cancer risk; we cannot extend the finding to entire mutations of RAD51D. Second, the numbers of RAD51D mutation carriers are small, and the association between RAD51D mutation carriers and worse survival should be confirmed in independent studies.
Conclusion
In conclusion, we found that 0.38% of BRCA1/2-negative breast cancer patients carry deleterious RAD51D germline mutations in this large cohort, RAD51D recurrent mutation p.K91fs accounts for 60% of the entire mutations in Chinese women with breast cancer, and p.K91fs confers a moderately increased risk for breast cancer. More importantly, RAD51D mutation carriers have an unfavorable survival, therefore raising a question whether RAD51D mutation carriers could benefit from targeted therapy.
Twenty-nine breast cancer patients (0.38%) carried RAD51D germline mutations among 7657 unselected breast cancer patients, and recurrent mutation p.K91fs was identified in 18 cases in this cohort. Our findings suggested that recurrent mutation p.K91fs confers a moderately increased breast cancer risk, and RAD51D mutation carriers have an unfavorable survival compared with noncarriers.
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